The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App 
Professionals >> Visit The Body PROThe Body en Espanol
AIDS 2006; Toronto, Canada; August 13-18, 2006

Key Links:

By Topic:


  • Email Email
  • Glossary Glossary
The Body Covers: The XVI International AIDS Conference
Abacavir Hypersensitivity Becoming Easier to Predict Using Pharmacogenetic Markers

August 16, 2006

Although abacavir (ABC, Ziagen) is a highly effective drug for the treatment of HIV, a drawback to its use is the risk of hypersensitivity reaction (HSR). To date, 8% of patients in clinical studies have experienced HSR, and some cases have proven fatal.1 The implementation of a clinical risk management program has successfully reduced the incidence of serious outcomes among patients on abacavir, but a highly predictive genetic marker could significantly improve the risk-benefit ratio even more. Multiple studies from Simon Mallal's group in Australia have shown that the human leukocyte antigen (HLA) allele HLA-B*5701 is highly associated with abacavir HSR in whites.2,3 Complementing Mallal's work, Michael Mosteller and colleagues from GlaxoSmithKline (Glaxo) presented a fascinating study4 on the pharmacogenetics behind abacavir hypersensitivity that aimed to answer several key questions:

  • Are there genetic markers in addition to HLA-B*5701 that are predictive of abacavir HSR?

  • Are there other genetic markers that, when considered in combination with HLA-B*5701, can enhance its predictive value?

  • How predictive is HLA-B*5701 in non-whites?

A total of 595 cases were retrospectively identified among individuals who were suspected of having abacavir HSR. These individuals were compared with 744 abacavir-treated control patients who had no evidence of abacavir HSR. Of the 1,339 individuals, 73% were white, 9% black, 10% Hispanic and 8% Asian (primarily Thai). Their mean age was 40.9 years, and 24% were female.

The predictive value of single and paired genetic markers was examined for both cases and controls. Racial groups were analyzed separately. Although several markers located throughout the genome were significantly associated with suspected abacavir HSR, the strongest associations involved markers located on chromosome 6 in the region surrounding HLA-B. In white individuals, HLA-B*5701 was most strongly associated with clinically suspected abacavir HSR, as shown in the table below, and no combination of markers exhibited sensitivities and specificities greater than those of HLA-B*5701 alone. The sensitivity and positive predictive value of HLA-B*5701 varied in non-whites, being highest in Asian individuals and lowest in blacks.

Performance Characteristics of HLA-B*5701, by Racial Group
Racial GroupWhitesBlacksHispanicsAsians (Thai)
Cases, n44450637
Controls, n4866770102
Genotypic P Value7.5x10-730.161.2x10-56.3x10-6
Sensitivity, %5082257
Specificity, %98999598
PPV, %53146787
NPV, %97969598
OR (95% CI)42.1 (22.8-77.8)4.3 (0.7-28.3)41.3 (2.4-708.7)263.6 (11.8-5909.1)

CI, confidence interval; NPV, negative predictive value; OR, odds ratio; PPV, positive predictive value.

Although the results in non-whites must be considered exploratory given the small sample sizes of the analyzed groups, HLA-B*5701 may be a useful marker for predicting abacavir HSR in Latinos and Thais -- more so than in blacks. Studies involving larger populations of non-white individuals are needed to verify these preliminary findings. Studies assessing different white subpopulations are also required to determine whether the predictive value of HLA-B*5701 is equally as strong across the entire racial group.

Clinical diagnosis of abacavir HSR is required for optimal management of the condition, but is quite difficult. HLA testing is a relatively inexpensive test that may improve the diagnostic accuracy of predicting abacavir HSR, especially when combined with skin patch testing. Two Glaxo studies incorporating skin patch testing have begun. PREDICT-1 is a prospective trial comparing the abacavir HSR rate between two groups of patients receiving standard abacavir treatment: a diverse group of patients and a group of patients who do not carry the HLA-B*5701 allele. The SHAPE study is a retrospective trial evaluating the performance characteristics of HLA-B*5701 in whites and blacks.

Abacavir has proven to be a potent and useful nucleoside analog for the treatment of HIV. Hopefully clinicians will soon be able to take better advantage of this effective agent by using HLA typing and/or skin testing to tailor abacavir use to the patients least likely to develop HSR.


  1. James A, Johann-Liang R. Increased rate and severity of abacavir-associated hypersensitivity reaction in randomized controlled clinical trials. In: Program and abstracts of the 12th Conference on Retroviruses and Opportunistic Infections; February 22-25, 2005; Boston, Mass. Abstract 835.

  2. Martin AM, Nolan D, Gaudieri S, et al. Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant. Proc Natl Acad Sci USA. March 23, 2004;101(12):4180-4185.

  3. Hughes AR, Mosteller M, Bansal AT, et al, on behalf of the CNA30027 and CNA30032 study teams. Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations. Pharmacogenomics. March 2004;5(2):203-211.

  4. Mosteller M, Hughes A, Warren L, et al. Pharmacogenetic (PG) investigation of hypersensitivity to abacavir. In: Program and abstracts of the XVI International AIDS Conference; August 13-18, 2006; Toronto, Canada. Abstract WEPE0171.
    View poster: Download PDF

  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by The Body PRO. Copyright © Body Health Resources Corporation. All rights reserved.

Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.